Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc., No. 14-1634 (Fed. Cir. Nov. 10, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Prometheus Laboratories, Inc. (“Prometheus”) appeals a judgment of the U.S. District Court for the District of New Jersey holding the amended claims of U.S. Patent No. 6,284,770 (“ the ’770 patent ”) invalid. The district court found the claims would have been obvious over the prior art or, in the alternative, invalid on grounds of obviousness-type double patenting over U.S. Patent No. 5,360,800 (“ the ’800 patent”).